Regulatory Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe Pharmaceutical TechnologyLilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.OncologyRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaceutical Technology Lilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults. Oncology Read full story Post navigation Previous: Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and ZepboundNext: Ipsen charts $1.75bn course for Kartos acquisition Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026